Pancreatic Cancer Research

ResearcherPurdue University West LafayetteActive in the last 2 years

Brittany L. Allen-Petersen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7436-9412; OpenAlex author ID A5052134233; NIH RePORTER profile ID 11725379. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 3)
Trials
0
Grants
4
Labs led
1
Collaborators
47
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper, 1 grant · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper, 2 grants · 2023: none · 2024: 2 papers · 2025: 5 papers · 2026: 1 paper, 1 grant

Papers 12

  1. Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. Last author DOI 10.1158/1535-7163.mct-25-0970↗
  2. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2024.12.003↗
  3. Protocol to purify and culture human pancreatic cancer cells from patient-derived xenografts. Co-author DOI 10.1016/j.xpro.2025.103672↗
  4. PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma Last author DOI 10.1101/2025.07.14.664742↗
  5. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Co-author DOI 10.1101/2025.07.14.664767↗
  6. The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
  7. Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells. Co-author DOI 10.1016/j.heliyon.2024.e27221↗
  8. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development. Last author DOI 10.1038/s41388-024-03196-w↗
  9. Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics14040713↗
  10. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-18-0717↗
  11. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Co-author DOI 10.1038/s41467-017-01967-6↗
  12. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. First author DOI 10.1158/1541-7786.mcr-13-0542↗

Grants 4

  1. Posttranslational regulation of macropinocytosis in pancreatic cancer R01CA295946↗
  2. The Role of PP2A in Regulating Pancreatic Cancer Macropinocytosis AWARD pancan:2022-brittany-allen-petersen-phd-the-role-of-pp2a-in-regulating-pancreati
  3. The role of PP2A B56a in pancreatic tumorigenesis K22CA237620↗
  4. MYC is a critical downstream effector in KRAS-driven pancreatic cancer F32CA192769↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 10 shared papers, 2014–2025 · strength 1.44
  2. Brett C. Sheppard · 7 shared papers, 2014–2025 · strength 0.89
  3. Jason M. Link · 4 shared papers, 2017–2025 · strength 0.62
  4. Garima Baral · 3 shared papers, 2024–2026 · strength 0.61
  5. Terry K. Morgan · 3 shared papers, 2024–2025 · strength 0.58
  6. Isabel A. English · 3 shared papers, 2024–2025 · strength 0.50
  7. Claire M. Pfeffer · 2 shared papers, 2025–2026 · strength 0.44
  8. Amy S. Farrell · 4 shared papers, 2014–2025 · strength 0.42
  9. Katherine R. Pelz · 3 shared papers, 2019–2025 · strength 0.41
  10. Dmytro Grygoryev · 2 shared papers, 2024–2025 · strength 0.41
  11. Jungsun Kim · 2 shared papers, 2024–2025 · strength 0.41
  12. Jennifer P. Morton · 3 shared papers, 2017–2026 · strength 0.35
  13. Kevin Hawthorne · 2 shared papers, 2025 · strength 0.33
  14. Motoyuki Tsuda · 2 shared papers, 2025 · strength 0.33
  15. Ellen M. Langer · 2 shared papers, 2025 · strength 0.33
  16. Vidhi M. Shah · 2 shared papers, 2022–2025 · strength 0.31
  17. Megan T. Hoffman · 2 shared papers, 2017–2025 · strength 0.26
  18. Howard C. Crawford · 2 shared papers, 2017–2025 · strength 0.26
  19. Meghan M. Joly · 2 shared papers, 2017–2025 · strength 0.22
  20. Patrick Joseph Worth · 2 shared papers, 2017–2025 · strength 0.22
  21. Julien Tessier · 1 shared paper, 2025 · strength 0.22
  22. Kathleen E. DelGiorno · 1 shared paper, 2025 · strength 0.21
  23. Nina G. Steele · 1 shared paper, 2025 · strength 0.21
  24. Daniel James Salas-Escabillas · 1 shared paper, 2025 · strength 0.21
  25. Simone Benitz · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.